Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk Read more
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases Read more
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline Read more
Novartis Scemblix FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile Read more
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline Read more
European Commission Approves DARZALEX (daratumumab)-SC Quadruplet Regimen for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Read more
Lilly’s Kisunla Gains Marketing Authorization in Great Britain for Alzheimer’s Treatment in Select Adult Patients Read more
Exelixis and Merck Partner to Advance Zanzalintinib Trials with KEYTRUDA in Head and Neck Cancer and WELIREG in Renal Cell Carcinoma Read more